1
|
Krieser K, Emanuelli J, Daudt RM, Bilatto S, Willig JB, Guterres SS, Pohlmann AR, Buffon A, Correa DS, Külkamp-Guerreiro IC. Taste-masked nanoparticles containing Saquinavir for pediatric oral administration. Mater Sci Eng C Mater Biol Appl 2020; 117:111315. [PMID: 32919675 DOI: 10.1016/j.msec.2020.111315] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 05/04/2020] [Accepted: 07/20/2020] [Indexed: 11/17/2022]
Abstract
This research has aimed to improve the stability and taste-masking properties by developing nanostructured dosage forms containing Saquinavir. Liquid formulations were developed using Eudragit RS100® and Pullulan as polymers. The physicochemical characteristics, stability, in vitro drug release, morphology, mucoadhesion and taste masking capacity were evaluated. The Saquinavir-nanoparticles had average diameters between 136 and 158 nm, with a Span below 1.4. These formulations presented a drug content above 80%, a high encapsulation efficiency (>97%), slightly acidic pH levels, low dynamic viscosity and controlled drug release. Electron microscopy revealed irregular spherical nanoparticles. The formulations prepared with higher amounts of Eudragit RS100® had greater mucoadhesion. Both polymers were able to improve drug stabilization, taste-masking properties and protection against drug cytotoxicity. The Saquinavir-nanoparticles exhibited stability and control releasing properties, thus making it a promising liquid dosage form with taste-masking properties intended for application in pediatric treatment.
Collapse
Affiliation(s)
- Katherine Krieser
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Avenida Ipiranga, 2572, Porto Alegre, RS 90610-000, Brazil
| | - Juliana Emanuelli
- Programa de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Avenida Ipiranga, 2752, Porto Alegre, RS 90610-000, Brazil
| | - Renata Moschini Daudt
- Departamento de Engenharia Química, UFRGS, Rua Engenheiro Luiz Englert s/n, Porto Alegre, RS 90040-040, Brazil
| | - Stanley Bilatto
- Laboratório Nacional de Nanotecnologia para o Agronegócio (LNNA), Embrapa Instrumentação, 13560-970 São Carlos, São Paulo, Brazil
| | - Julia Biz Willig
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Avenida Ipiranga, 2572, Porto Alegre, RS 90610-000, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Avenida Ipiranga, 2752, Porto Alegre, RS 90610-000, Brazil
| | - Silvia Stanisçuaski Guterres
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Avenida Ipiranga, 2572, Porto Alegre, RS 90610-000, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Avenida Ipiranga, 2752, Porto Alegre, RS 90610-000, Brazil
| | - Adriana Raffin Pohlmann
- Programa de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Avenida Ipiranga, 2752, Porto Alegre, RS 90610-000, Brazil.; Departamento de Química Orgânica, Instituto de Química, UFRGS, CP15003, Av. Bento Gonçalves, 9500, Porto Alegre, RS 91501-970, Brazil
| | - Andréia Buffon
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Avenida Ipiranga, 2572, Porto Alegre, RS 90610-000, Brazil
| | - Daniel Souza Correa
- Laboratório Nacional de Nanotecnologia para o Agronegócio (LNNA), Embrapa Instrumentação, 13560-970 São Carlos, São Paulo, Brazil
| | - Irene Clemes Külkamp-Guerreiro
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Avenida Ipiranga, 2572, Porto Alegre, RS 90610-000, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Avenida Ipiranga, 2752, Porto Alegre, RS 90610-000, Brazil..
| |
Collapse
|
3
|
Abstract
OBJECTIVE The purpose of this study was to examine the stability of a generic lansoprazole product in a 3 mg/mL sodium bicarbonate suspension under room temperature and refrigerated conditions. METHODS Lansoprazole suspensions (3 mg/mL) were prepared in triplicate using an 8.4% sodium bicarbonate vehicle for each storage condition (room temperature and refrigerated). During 1 month, samples from each replicate were periodically removed and analyzed for lansoprazole concentration by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Each sample was spiked with 10 mg/L omeprazole to serve as the internal standard. A positive electrospray LC-MS/MS method was validated over the calibration range of 5 to 25 mg/L using Food and Drug Administration Guidance. The identities of the analyte and internal standard in the samples were verified by monitoring the MS/MS transitions of m/z 370 to m/z 252 and m/z 346 to m/z 198 for lansoprazole and omeprazole, respectively. Additionally, the pH of the suspensions was monitored throughout the study. RESULTS The stability of lansoprazole in the oral sodium bicarbonate suspension under refrigeration is compromised prior to what has been previously reported in the literature. Samples kept at room temperature lost >10% of the lansoprazole after 48 hours compared with the refrigerated samples, which maintained integrity up to 7 days. No statistically significant difference was found between the pH of the room temperature and refrigerated suspension samples, indicating that this factor is not the cause for the differences in stability at these two conditions. CONCLUSIONS This study suggests that the extemporaneously compounded lansoprazole oral suspension prepared in 8.4% sodium bicarbonate should not be stored in plastic oral syringes longer than 48 hours at room temperature and no longer than 7 days when refrigerated. These data indicate an expiration time earlier than that previously reported for the refrigerated product (14 days).
Collapse
Affiliation(s)
- Jordan T. Morrison
- Department of Pharmaceutical Sciences East Tennessee State University, Johnson City, Tennessee
| | - Ralph A. Lugo
- Department of Pharmacy Practice, East Tennessee State University, Johnson City, Tennessee
| | - Jim C. Thigpen
- Department of Pharmacy Practice, East Tennessee State University, Johnson City, Tennessee
| | - Stacy D. Brown
- Department of Pharmaceutical Sciences East Tennessee State University, Johnson City, Tennessee
| |
Collapse
|
4
|
Abstract
Protease inhibitors (PIs) are potent competitive inhibitors of the human immunodeficiency virus (HIV) widely used in the treatment of the acquired immune deficiency syndrome (AIDS) and prescribed in combination with other antiretroviral drugs. So far ten PIs were approved by the United States Food and Drug Administration (FDA) for the treatment of HIV infection. In this mini review, quality control methods of each PI are discussed on the basis of analytical techniques published in the literature. Special attention is given to summarize the LC methods described for the analysis of the selected PIs in both drug substances and products with the available literature till date.
Collapse
Affiliation(s)
- Raja Yekkala
- Laboratory for Pharmaceutical Analysis, Faculty of Pharmaceutical Sciences, K.U. Leuven, O&N 2, Postbox 923, Herestraat 49, B-3000 Leuven, Belgium
| | | | | | | |
Collapse
|